Comparison between Semaglutide vs Tirzepatide
| Parameter | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Mechanism | GLP-1 receptor activation | Dual incretin activation |
| Onset | Gradual | Gradual |
| Monitoring | None | None |
| Dosing | Weekly titration | Weekly titration |
| Half-life | Long (~1 week) | ~5 days |
| Reversal Agent | None | None |
| Bleeding Risk | Low | Low |
| Indications | T2DM/weight | T2DM/weight |
| Renal Use | No adjust | Limited ESRD data |
| Pregnancy Use | Avoid | Avoid |
| Drug Interactions | Gastric delay | Gastric delay |
| Adherence Sensitivity | Moderate | Moderate |
| Best Use Case | Standard GLP1 | Stronger metabolic effect |
| Cost | High | High |
| Monitoring Burden | Low | Low |
| Clinical Flexibility | Moderate | Moderate |
| Real-world Convenience | High | High |
| Overall Verdict | Established option | More potent option |
| Food Interactions | None | None |